• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023

    3/24/23 8:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $BIAF alert in real time by email

    Conference Call scheduled on April 3, 2023, at 9 a.m. Eastern time

    bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a conference call on Monday, April 3, 2023, at 9:00 a.m. Eastern time to discuss those results and answer questions.

    Event:

         

    bioAffinity Technologies Fourth Quarter 2022 Financial Results

    Date:

         

    Monday, April 3, 2023

    Time:

         

    9:00 a.m. EDT

    Toll Free:

         

    1-877-270-2148

    International:

         

    1-412-902-6510

    Webcast:

         

    Webcast link

    A replay of the event will be available for 90 days at the webcast link above, which can also be found in the Investor Relations section of bioAffinity's website at ir.bioaffinitytech.com.

    About bioAffinity Technologies, Inc.

    bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. The Company's first product, CyPath® Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services. OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company's platform technologies are conducted in its laboratories at The University of Texas at San Antonio. For more information, visit www.bioaffinitytech.com.

    Forward-Looking Statements

    This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company's offering of common shares. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230324005073/en/

    Get the next $BIAF alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BIAF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIAF
    SEC Filings

    See more
    • SEC Form POS AM filed by bioAffinity Technologies Inc.

      POS AM - bioAffinity Technologies, Inc. (0001712762) (Filer)

      6/27/25 4:53:08 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form POS AM filed by bioAffinity Technologies Inc.

      POS AM - bioAffinity Technologies, Inc. (0001712762) (Filer)

      6/27/25 4:50:32 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEFA14A filed by bioAffinity Technologies Inc.

      DEFA14A - bioAffinity Technologies, Inc. (0001712762) (Filer)

      6/2/25 5:29:21 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on cancer diagnostics and targeted therapeutics, will present findings today related to the discovery of a potential broad-spectrum cancer therapy that is the subject of the Company's recently issued U.S. Patent No. 12,305,171 and the notification of patent grant from the China National Intellectual Property Administration. The presentation at the 2025 RNA Therapeutics Conference, titled "Silencing CD320 and LRP2 by siRNAs selectively kills cancer cells: mechanistic enigmas," highlights a novel therapeutic approach that uses small interfering RNAs (siRNAs) to selectively kill cancer cells by targeting tw

      6/26/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

      Company research targets topical application for treatment of skin cancers bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company's novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane. The newly allowed Chinese patent – titled "Compositions and Methods for Treating Cancer" – adds important global protection for bioAffinity's innovative RNA-based therapeutic strategy and covers siRNAs

      6/24/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas' Leadership Board, a distinguished group of healthcare professionals and advocates committed to advancing lung health. As a member of the Texas Leadership Board, Ms. Zannes will play an important role in supporting the Lung Association's mission to improve lives by preventing lung disease and promoting lung health through research, education and advocacy. Board

      6/11/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Reveles Xavier Trinidad was granted 21,604 shares, increasing direct ownership by 106% to 41,943 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:26 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Secretary, EVP, Gen. Counsel Zannes Timothy P was granted 8,641 shares, increasing direct ownership by 19% to 54,765 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:20 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • President & CEO Zannes Maria was granted 37,037 shares, increasing direct ownership by 15% to 280,359 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:23 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Financials

    Live finance-specific insights

    See more
    • Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ENLV: https://www.redchip.com/assets/access/enlv_accessBIAF: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a c

      1/10/25 9:00:00 AM ET
      $BIAF
      $ENLV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (NASDAQ:BTCY) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Biotricity: https://www.redchip.com/assets/access/btcy_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of car

      7/12/24 9:35:00 AM ET
      $BIAF
      $BTCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Medical/Dental Instruments
    • BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs target

      7/5/24 9:00:00 AM ET
      $BIAF
      $BIVI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BIAF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by bioAffinity Technologies Inc.

      SC 13G - bioAffinity Technologies, Inc. (0001712762) (Subject)

      10/10/23 6:03:06 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Leadership Updates

    Live Leadership Updates

    See more
    • bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas' Leadership Board, a distinguished group of healthcare professionals and advocates committed to advancing lung health. As a member of the Texas Leadership Board, Ms. Zannes will play an important role in supporting the Lung Association's mission to improve lives by preventing lung disease and promoting lung health through research, education and advocacy. Board

      6/11/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role. Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved resea

      5/20/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

      Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) ("bioAffinity" or the "Company"), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 as Senior Vice President of Research and Development, Dr. Bauta was the Associate Director of Science at Genzyme Corporation and held a similar positi

      11/4/24 8:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care